Anaphylaxis Clinical Trial
Official title:
Investigation of Hematologic Parameters in Mastocytosis and Idiopathic Anaphylaxis
This study will 1) identify characteristics of bone marrow mast cells in patients with
unexplained anaphylaxis and flushing or with mastocytosis and 2) determine whether
mastocytosis might be the underlying cause of unexplained anaphylaxis in some patients with
this condition. Anaphylaxis is a hypersensitivity reaction in which patients may have
flushing, hives, stuffy nose, red itchy eyes, difficulty breathing, swelling of the tongue,
throat, palms and soles, abdominal cramping, lightheadedness, decreased blood pressure, and
loss of consciousness. Although allergens are a common cause of anaphylactic episodes, no
cause can be identified in up to 50 percent of patients who have recurrent events.
Mastocytosis is a disease of excessive mast cells in tissues such as skin and bone marrow.
These cells can release chemicals that result in itching, blisters, flushing, bone pain, and
abdominal pain.
Patients 18 years of age and older who have episodes of anaphylaxis or flushing with no
apparent cause or who have mastocytosis may be eligible for this study. Participants will
have a medical history and physical examination; blood tests to identify genetic changes
that are important in the growth, development, and functioning of human mast cells; and bone
marrow aspiration and biopsy. For the bone marrow procedure, the skin over the hipbone and
the outer surface of the bone itself are numbed with local anesthesia. Then, a special
needle is inserted into the hipbone and about 1 tablespoon of bone marrow is drawn into a
syringe. Another needle is inserted into the same area to collect a small piece of the bone
marrow. Additional procedures may include allergen testing, urinalysis, and 24-hour urine
collection.
Participants will return to NIH for reassessment of disease status in 12 to 18 months. The
follow-up evaluation will include a history and physical examination, blood tests, possible
repeat bone marrow and aspiration in patients whose clinical signs or symptoms change
significantly, and other tests as clinically indicated.
First-degree relatives (parents, children, siblings) may be enrolled in limited instances to
provide a blood sample for genetic analysis related to mast cell development and function
for comparison with that of patients when they have similar symptoms.
Status | Completed |
Enrollment | 100 |
Est. completion date | August 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA FOR PATIENTS WITH MASTOCYTOSIS: Age equal to or greater than 18 years. Diagnosis of mastocytosis established by presence of typical urticaria pigmentosa skin lesions or a bone marrow biopsy. Letter of referral from prospective study participant's local doctor. Ability to give informed consent. EXCLUSION CRITERIA FOR PATIENTS WITH MASTOCYTOSIS: Age less than 18 years. Lack of a referral physician. Presence of co-morbid conditions which, in the judgment of the investigator or the referring physician, may put the patient at undue risk for travel (such as an acute infection, severe thrombocytopenia). Inability to provide informed consent. Inability or refusal to undergo a bone marrow biopsy and aspirate. Known allergy to latex or Lidocaine. INCLUSION CRITERIA FOR PATIENTS WITH UNEXPLAINED FLUSHING OR ANAPHYLAXIS: Age equal to or greater than 18 years. Presence of flushing or anaphylaxis with negative workup for known causes such as carcinoid syndrome, pheochromocytoma, food allergy. Ability to give informed consent. EXCLUSION CRITERIA FOR PATIENTS WITH UNEXPLAINED FLUSHING OR ANAPHYLAXIS: Same as for patients with mastocytosis. Known cause for anaphylaxis or flushing. Frequent life-threatening anaphylactic episodes: History of 6 or more separate attacks resulting in ER visits in the 6 months preceding the referral. INCLUSION CRITERIA FOR RELATIVE: To have a first-degree relative accepted to the protocol as a patient with unexplained anaphylaxis, flushing or mastocytosis. Ability to give informed consent. For minors, ability of the parent to give informed consent. There are no age restrictions. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000 Feb;28(2):140-7. — View Citation
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001 Jan 8;161(1):15-21. Review. — View Citation
Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002 Jul 15;100(2):661-5. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04475003 -
Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Active, not recruiting |
NCT03953482 -
Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
|
||
Recruiting |
NCT05112367 -
Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
|
||
Completed |
NCT03366298 -
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
|
Phase 4 | |
Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
Completed |
NCT04696822 -
Bioavailability of Nasal Epinephrine
|
Phase 1 | |
Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
Completed |
NCT02854969 -
Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device
|
N/A | |
Completed |
NCT03282929 -
Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)
|
Phase 1 | |
Recruiting |
NCT01326741 -
Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis
|
N/A | |
Recruiting |
NCT06445374 -
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges
|
Phase 1 | |
Completed |
NCT01217138 -
Make up for the Epinephrine Autoinjector
|
Phase 4 | |
Completed |
NCT02424136 -
PEAnut Anaphylaxis Predictors
|
N/A | |
Completed |
NCT01432522 -
A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine
|
N/A | |
Completed |
NCT02028065 -
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
|
Phase 1 | |
Active, not recruiting |
NCT01247415 -
Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
|
N/A | |
Completed |
NCT00868842 -
Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis
|
N/A | |
Completed |
NCT04290507 -
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
|